Update shared on19 Sep 2025
Fair value Increased 1.63%Given the absence of analyst reasoning, the consensus analyst price target for Lonza Group saw only a marginal increase from CHF665.36 to CHF676.18 alongside minimal changes in key valuation metrics such as future P/E and discount rate, indicating steady market expectations and a broadly unchanged fair value outlook.
What's in the News
- Lonza entered a seven-year manufacturing agreement with Avidity Biosciences for commercial drug substance and product, with a minimum purchase commitment of approximately $620 million between 2026 and 2028.
- Lonza, Excellos, and Akadeum Life Sciences launched a collaborative project to advance cell therapy manufacturing, focusing on improving starting material quality and integrating automated, modular workflows.
- Lonza raised its 2025 full-year CDMO sales growth guidance to 20%–21% in constant currency.
Valuation Changes
Summary of Valuation Changes for Lonza Group
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from CHF665.36 to CHF676.18.
- The Future P/E for Lonza Group remained effectively unchanged, moving only marginally from 31.35x to 31.82x.
- The Discount Rate for Lonza Group remained effectively unchanged, moving only marginally from 4.37% to 4.43%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.